Navigation Links
NKTR-102 Demonstrates Sustained Clinical Benefit in 46% of Patients with Metastatic Breast Cancer in Data Presented at 2011 American Society of Clinical Oncology Annual Meeting
Date:6/4/2011

CHICAGO and SAN FRANCISCO, June 4, 2011 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced positive results from a Phase 2 clinical study evaluating single-agent NKTR-102 as a second- and third-line treatment in patients with metastatic breast cancer during the 2011 American Society of Clinical Oncology Meeting (ASCO).  NKTR-102, a next-generation topoisomerase I inhibitor, is Nektar's lead oncology drug candidate and is being evaluated in multiple cancer indications.  The randomized Simon two-stage study presented at ASCO evaluated two 145 mg/m2 dose schedules of single-agent NKTR-102, every two weeks (q14d) and every three weeks (q21d), in 70 metastatic breast cancer patients who failed a prior taxane therapy.  Eighty-nine percent (62/70) of patients in the study received a prior anthracycline/taxane with or without capecitabine.

More than one million women worldwide are diagnosed with breast cancer every year and the disease is the leading cause of cancer-related death among women.(1)  

A total of 66 of the 70 patients treated with single-agent NKTR-102 in the Phase 2 study were assessable for the primary endpoint of objective tumor response rate (ORR), including confirmed complete responses (CRs) and partial responses (PRs) per RECIST 1.0.  As of May 9, 2011, for the q14d day schedule, the confirmed and unconfirmed ORR was 35 percent (11/31) and the confirmed ORR was 32 percent (10/31), including two confirmed CRs.  Clinical benefit rate for the 31 evaluable patients in the q14d schedule was 42% (13/31) (defined as confirmed CR+ PR+ Stable Disease (SD) >6 mos).  For the q21d schedule, the confirmed and unconfirmed ORR was 31 percent (11/35) and the confirmed ORR was 26 percent (9/35).  Clinical benefit rate for the 35 evaluable patients in the q21d schedule was 49% (17/35).  Clinical benefit rate for t
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Tumor Growth Inhibition and Pharmacokinetic Profile of NKTR-102 (PEG-Irinotecan) in Multiple Solid Tumors To Be Presented at Upcoming AACR-NCI-EORTC International Conference
2. NKTR-102 (PEG-Irinotecan) Demonstrates Significant Tumor Growth Inhibition In Multiple Preclinical Tumor Models
3. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
4. Additive Anti-Tumor Activity of NKTR-102 in Combination With Bevacizumab Highlighted in Positive Preclinical Data Presented at AACR Meeting
5. Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings
6. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
7. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
8. NKTR-102 Shows Encouraging Anti-Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplinary Congress
9. NKTR-102 Demonstrates Significant Efficacy as Single-Agent in Second- or Third-Line Treatment in Metastatic Breast Cancer Patients
10. FDA Grants Orphan Drug Designation for Nektars Investigational Drug, NKTR-102, for Treatment of Women with Ovarian Cancer
11. Nektar Announces New Phase 2 Data for NKTR-102 to Be Presented at 2011 ASCO Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... 2014 Research and Markets ( ... "MEMS Gyroscopes Analog Devices ADIS16136 Precision Angular ... their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... applications made a lot of progress in the ... are now accepted in high-reliability environments, and are ...
(Date:12/15/2014)... BERGEN, Norway , December 15, 2014 ... developing innovative drugs for aggressive drug resistant cancers, today ... million) in a private placing from new and existing ... the financing to support the development of its pipeline ... development program for its lead drug candidate, BGB324, a ...
(Date:12/15/2014)... and Washington State are not the ... Oregon , Alaska , and ... November 2014 elections. Photo - http://photos.prnewswire.com/prnh/20141212/164152 ... The benefits of legalizing cannabis are manifold. There are ... tax revenue for state and local governments, in addition to ...
Breaking Medicine Technology:MEMS Gyroscopes Analog Devices ADIS16136 Precision Angular Rate Sensor Reverse Costing Analysis 2BerGenBio Completes NOK90 Million Fundraising 2CannaInsider.com Estimates 200,000 New Jobs in the Cannabis Industry by 2015 2
... 8, 2011 UBM Canon announced today at MD&M West ... Qmed to build on its success since its ... Canon Data Mine (CDM) database product will become part ... and sourcing platform for medical device OEMs. As part of ...
... 2011 /PRNewswire-Asia-FirstCall/ -- Tianyin Pharmaceutical Co., Inc., (NYSE ... that develops, manufactures and markets patented biopharmaceutical, modernized ... today announced that the senior management will host ... 2011 second quarter financial results at 8:30 a.m. ...
Cached Medicine Technology:UBM Canon Announces Significant Investment and Development Plans for the Next Generation of Qmed.com 2UBM Canon Announces Significant Investment and Development Plans for the Next Generation of Qmed.com 3Tianyin Pharmaceutical Co., Inc. to Host Fiscal Year 2011 Second Quarter Earnings Conference Call on Tuesday, February 15, 2011 at 8:30 a.m. E.T. 2
(Date:12/17/2014)... -- Expectant parents should leave prenatal picture-taking to medical ... Use of ultrasound imaging and heartbeat monitors to get ... agency warns. "Although there is a lack ... and heartbeat monitors, prudent use of these devices by ... FDA biomedical engineer, said in an agency news release. ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. 16, ... America, and work commitment is a big reason why, new ... said Dr. Mathias Basner, an assistant professor of sleep and ... of Medicine. A time-use survey of nearly 125,000 Americans, ... main activity exchanged for sleep. Short sleepers -- those who ...
(Date:12/15/2014)... 15, 2014 South Florida’s leading urgent care ... can be a daze of hassle, hustle, and bustle that ... decking halls, to burns when making special meals and heartburn ... can happen at any time. To prevent this season of ... made a list of helpful and healthful holiday tips to ...
(Date:12/15/2014)... News) -- Expert pilots process visual information more efficiently ... better decisions during landings, a new study shows. ... pilots to master, and 36 percent of all airplane ... final approach and landing. Researchers monitored the brain ... pilots while they were at the controls of a ...
(Date:12/15/2014)... 15, 2014 At the leading, long-established ... AutismOne and Focus Autism will welcome ... research on the effects of toxins to children’s health, ... information. , Luminaries such as Dr. Lucija Tomljenovic ... with esteemed, credentialed colleagues of the United States to ...
Breaking Medicine News(10 mins):Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3Health News:MD Now Urgent Care Presents Healthy Holiday Tips 2Health News:MD Now Urgent Care Presents Healthy Holiday Tips 3Health News:Study Shows Why Expert Pilots Are Experts 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 3
... reported a study that confirms the findings of ... between juvenile stroke and migraine in women. The ... of age with first-ever ischaemic stroke or transient ... controls, in the study. They excluded patients who ...
... study by researchers at Kansas State University has ... matrix within the umbilical cord, is a rich ... These umbilical cord matrix cells, which show tell-tale ... scientific and medical research community with a non-controversial ...
... study, by researchers in Colorado, claims that patients recovering ... and massage therapy. Researchers said that in the recent ... which have been shown by research to have a ... massage therapy have received much scrutiny. Researchers, who explained ...
... Schering-Plough as therapy in the control and management of ... years of age and older. It was launched in ... be launched in the other European Union(EU) markets, in ... inhaler, contains the orally// inhaled corticosteroid mometasone furoate, which ...
... A new study by researchers at the University of Texas ... history of kidney stones, which makes them absorb too much ... risk of kidney stones, because they cause too much calcium ... also added that people with kidney stones had a greater ...
... potential medical problems, according to earlier studies, is three times ... in hospitals are even higher. However, a new effort by ... Healthcare Research and Quality (AHRQ) may help prevent medical errors ... at pediatricians and parents, and includes a fact sheet that ...
Cached Medicine News:
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: